Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition~* FEV1\> 70% of predicted normal value pre-bronchodilator~Exclusion Criteria:~* Having a known or suspected allergy to study therapy (active drugs or additive)~* Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure~* Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids within 3 months~* Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- First Symbicort, then Terbutaline (Type: EXPERIMENTAL): Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
- First Turbuhaler, then Symbicort (Type: EXPERIMENTAL): Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,

Based on this trial design, predict the completion outcome and termination type (if applicable).